Daniel Chevallard reports a stock award at LENZ Therapeutics
By AlphaYouPublished Form 4
Chevallard Daniel R.
Reporting filer
Daniel Chevallard reports a stock award, not an open-market purchase or sale, in LENZ Therapeutics, Inc.. Form 4 filed Nov 4, 2026 lists 1 entry.
- Disclosed
- Nov 4, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) (derivative) | Chevallard Daniel R. | 2026-10-30 | A | Grant or award | 652063 | 0 | 652,063 | 5 days | Filed terms
|
Stock Option (right to buy) (derivative)
- Owner
- Chevallard Daniel R.
- Date
- 2026-10-30
- Code
- A
- Action
- Grant or award
- Quantity
- 652063
- Price
- 0
- Following holdings
- 652,063
- Reporting delay
- 5 days
- Filed terms and references
Filed terms
- security Title: Stock Option (right to buy)
- conversion Or Exercise Price: 3.05
- transaction Date: 2026-10-30
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- transaction Shares: 652063
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- id: F1
- expiration Date: 2036-10-29
- underlying Security Title: Common Stock
- underlying Security Shares: 652063
- shares Owned Following Transaction: 652063
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Chevallard Daniel R.: Chief Financial Officer.
- F1: Subject to the Reporting Person serving as the Issuer's Interim President and CEO through each applicable date, the shares subject to the option shall vest in four equal tranches, as follows: 25% of the shares subject to the option shall commence vesting on November 1, 2026 and vest in full on November 1, 2027; 25% of the shares subject to the option shall commence vesting on February 1, 2027 and vest in full on February 1, 2028; 25% of the shares subject to the option shall commence vesting on May 1, 2027 and vest in full on May 1, 2028; 25% of the shares subject to the option shall commence vesting on August 1, 2027 and vest in full on August 1, 2028. If the Reporting Person ceases to serve as the Issuer's Interim President and CEO for any reason, any tranche for which the vesting commencement date has not yet occurred will be forfeited, and any tranche for which the vesting commencement date has occurred will remain eligible to vest.
Original sources
Prepared automatically from public filing data. Report a correction.